Today: 8 June 2026
Browse Category

NASDAQ:AMGN 4 November 2025 - 21 December 2025

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen (AMGN) Stock Week Ahead Forecast: Drug-Price Deal Fallout, Analyst Targets, and Year-End Catalysts to Watch (Dec. 22–26, 2025)

Amgen shares last traded near $327.38 as investors weighed a new FDA label expansion and U.S. drug-pricing deals announced Dec. 19. The NYSE will close early Dec. 24 and remain shut Dec. 25, thinning liquidity and increasing volatility risk. Amgen, a Dow component, remains sensitive to policy headlines and year-end positioning.
21 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen (AMGN) Stock Near Record Highs on Obesity Drug Hopes – Is It Still a Buy in December 2025?

Amgen traded near $343 Thursday, close to record highs after a year of strong earnings and FDA approval for its lung-cancer drug Imdelltra. Shares are up about 34% year-to-date, outpacing the broader market. Trefis set a bullish $450 target, citing 12% revenue growth and $13 billion in free cash flow. EverSource Wealth Advisors cut its Amgen stake by nearly 28% in Q2.
4 December 2025
··
Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally

Amgen shares closed at $345.42 on December 3, 2025, up 2% and setting a new 52-week high near $345.95. The stock has gained about 35% year-to-date and over 25% in the past year. Amgen beat Q3 earnings forecasts and raised full-year guidance, but analysts’ 12-month targets mostly remain below current prices. The consensus rating ranges from “Hold” to “Moderate Buy.”
3 December 2025
··
Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen (AMGN) Stock Today: Earnings Momentum, Obesity Breakthroughs and Fresh December 2, 2025 Forecasts

Amgen shares traded at $338.67 on December 2, 2025, up 0.35% and near 52-week highs after strong Q3 results and a raised 2025 outlook. Several institutional investors disclosed reduced AMGN holdings in Q2 filings. Technical analysts flagged a short-term bullish setup. The company’s obesity and cardiovascular drugs remain key pipeline drivers.
2 December 2025
···
Nasdaq Stumbles as Fed Jitters Mount, Intel Soars, Tariffs Rattle Tech Markets

AI Rally Hits Speed Bump as Futures Fall – Key Facts Before the Nov. 4 Market Open

U.S. stock futures fell sharply early Tuesday, with Nasdaq 100 futures down 1.2% and S&P 500 off 0.9%. The drop follows a stalled tech rally and overnight losses in Europe and Asia. Key economic data releases are delayed by a government shutdown, adding to market uncertainty. Palantir shares slid over 4% despite strong earnings, while Bitcoin dropped 3% to around $104,000.
4 November 2025
···········
1 2

Stock Market Today

  • S&P 500 and Dow Futures Dip Amid Renewed Iran-Israel Tensions Following Missile Attack
    June 8, 2026, 2:14 AM EDT. U.S. stock futures showed mixed signals as Iran launched its first missile attack on Israel since April, sparking fears of a ceasefire breakdown and geopolitical risk. The Dow Jones futures fell 0.33% and S&P 500 futures edged down 0.02%, while Nasdaq 100 futures showed a modest gain of 0.29%. Last week, major indexes suffered significant losses with Nasdaq dropping 4.18%, S&P 500 down 2.64%, and Dow falling 1.35%, driven by tech sector selloff and escalating Middle East tensions. U.S. President Donald Trump reportedly advised Israeli Prime Minister Netanyahu against retaliation to preserve progress in nuclear negotiations with Iran. Oil futures rose on heightened Middle East uncertainty. ETFs like SPDR S&P 500 (SPY) and Invesco QQQ (QQQ) edged higher amid bullish sentiment, contrasting with weakness in Dow and Treasury bond ETFs.

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop